Supervised Exercise and Revascularization for Intermittent Claudication

The combination of optimal medical treatment plus angioplasty plus supervised exercise seems to be the first line of treatment for patients with intermittent claudication, in terms of maximum walking distance and best quality of life. This combination requires a multidisciplinary team for the best possible results.

Continuar con la actividad física luego de un IAM reduce la mortalidad

The aim of this study was to conduct a meta-analysis comparing all therapeutic strategies for intermittent claudication, including optimal medical treatment, peripheral angioplasty, supervised exercise therapy, and their corresponding combinations, in order to determine the best treatment for intermittent claudication.

Intermittent claudication is a common problem that limits physical activity, decreases quality of life, and is associated with more cardiovascular events. There are previous meta-analyses, but none tested the impact of strategy combinations.

This study included data from 37 randomized studies, reaching almost 3000 patients with intermittent claudication (mean age was 68 years; 54.5% of patients were men). Comparisons were established between best medical treatment vs. supervised exercise vs. angioplasty vs. angioplasty plus supervised exercise.


Read also: Many Guidelines, Much Confusion. Blood Pressure Targets in the Elderly.


Angioplasty plus supervised exercise outperformed all other possible treatment strategies and obtained the maximum walking distance gain, 290 meters (p < 0.001).

As regards quality of life, the combination of angioplasty and supervised exercise also outperformed all other strategies. This does not mean that optimal medical treatment should be overlooked, since it acts over the whole range of cardiovascular disease.

The best course of action is a combination of all three strategies: optimal medical treatment aimed at a long/medium-term reduction in events (all cardiovascular events), angioplasty so that the patient experiences an acute difference and is able to begin with a supervised exercise plan, and, finally, such plan for result optimization and maintenance over time.

Original Title: Supervised Exercise Therapy and Revascularization for Intermittent Claudication Network Meta-Analysis of Randomized Controlled Trials.

Reference: Athanasios Saratzis et al. J Am Coll Cardiol Intv 2019, Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...